First Stage Investor

Startup Insider: 20/20 GeneSystems Pivots, Builds New Partnership

Startup Insider: 20/20 GeneSystems Pivots, Builds New Partnership
By Early Investing
Date September 19, 2022

20/20 GeneSystems has been busy. We first recommended the company in December 2017 when we learned about its incredible cancer detection technology. 20/20 GeneSystems identifies cancer risk early on by using tumor antigen markers. It can improve cancer detection by up to 30% through its proprietary machine learning algorithm.

In 2020, the company pivoted to COVID testing. At its peak, 20/20 GeneSystems provided 1,200 to 1,300 tests a day. The numbers have dropped since then, but the company’s momentum hasn’t slowed down. It’s acquiring new laboratory infrastructure, licensing intellectual property and building new partnerships. It’s also raising again on StartEngine.

In this episode of Startup Insider, Vin Narayanan and Allison Brickell sit down with 20/20 GeneSystems founder Jonathan Cohen to learn more about his company’s progress over the last few years. Topics include how the cancer detection industry has evolved, why 20/20 GeneSystems’ partnership with BioInfra is important for its OneTEST and what the company needs to scale into a much larger business.

Thanks for watching!

Top Posts on Early Investing